04/23/2026
While the incidence of many major cancers is flat or declining, esophageal adenocarcinoma continues to rise.
Over the past four decades, cases have increased more than 500% in the U.S.—yet awareness and screening have not kept pace.
Today, esophageal cancer remains one of the most lethal cancers, with a five-year survival rate of just ~20%.
What makes this especially challenging: it’s often silent until it’s advanced.
What makes it especially important: it’s often preventable.
Esophageal adenocarcinoma typically develops from Barrett’s Esophagus—a precancerous condition that can be detected before cancer forms. Yet more than 90% of patients diagnosed were never identified at the precancer stage.
At least 30 million at-risk Americans with chronic heartburn (GERD) are recommended for screening under major clinical guidelines—but most go unscreened.
At Lucid Diagnostics, we’re focused on enabling a different strategy—one centered on identifying esophageal precancer earlier, before it progresses to cancer.
The EsoGuard® DNA test offers a non-endoscopic, in-office approach to detecting precancer—helping direct the right patients to further evaluation.
Because when incidence is rising,
early detection isn’t optional—it’s essential.